<p>随着业务可能达到一个重要的里程碑，我们认为有必要更深入地了解 <strong>Avadel Pharmaceuticals plc（纳斯达克：AVDL）</strong> 的未来前景。Avadel Pharmaceuticals plc 是一家在美国运营的生物制药公司。这家市值为 7.42 亿美元的公司在 2024 年 12 月 31 日公布了最新的亏损为 4900 万美元，作为其最近的财务年度结果。由于盈利之路是 Avadel Pharmaceuticals 投资者关注的话题，我们决定评估市场情绪。在本文中，我们将讨论对公司增长的预期以及分析师预计何时会实现盈利。</p>
<p>特朗普承诺要 “释放” 美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
<p>根据覆盖 Avadel Pharmaceuticals 的 10 位行业分析师的共识，盈亏平衡点即将到来。他们预计公司将在 2024 年遭受最后一次亏损，然后在 2025 年实现 1500 万美元的正利润。因此，预计公司将在大约 12 个月内或更短时间内实现盈亏平衡。我们计算了公司必须以多快的速度增长才能满足预测在 12 个月内实现盈亏平衡的共识预测。结果显示，预计平均年增长率为 48%，这表明分析师对公司的信心很高。如果业务增长速度较慢，盈利的时间将会比预期更晚。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/28567-earnings-per-share-growth-1-dark/1744550329605?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/28567-earnings-per-share-growth-1-dark/1744550329605"/></p>
<p>纳斯达克 GM:AVDL 每股收益增长 2025 年 4 月 13 日</p>
<p>鉴于这是一个高层次的概述，我们不会详细讨论 Avadel Pharmaceuticals 即将推出的项目，但请记住，通常制药公司的现金流波动较大，这取决于药物和产品开发阶段。因此，特别是在公司处于投资期时，高增长率并不罕见。</p>
<p>查看我们对 Avadel Pharmaceuticals 的最新分析</p>
<p>我们想要强调的一点是 Avadel Pharmaceuticals 相对较高的债务水平。一般来说，经验法则是债务不应超过股本的 40%，而在 Avadel Pharmaceuticals 的情况下为 50%。较高的债务水平需要更严格的资本管理，这增加了投资于这家亏损公司的风险。</p>
<h2>下一步：</h2>
<p>Avadel Pharmaceuticals 的一些关键基本面在本文中未被覆盖，但我们必须再次强调，这仅仅是一个基本概述。要更全面地了解 Avadel Pharmaceuticals，请查看 Avadel Pharmaceuticals 在 Simply Wall St 的公司页面。我们还整理了一份您应该关注的关键因素清单：</p>
<ol>
<li><strong>估值</strong>：Avadel Pharmaceuticals 今天值多少钱？未来的增长潜力是否已经反映在价格中？我们免费研究报告中的内在价值信息图有助于可视化 Avadel Pharmaceuticals 目前是否被市场低估。</li>
<li><strong>管理团队</strong>：经验丰富的管理团队能够增强我们对业务的信心——请查看 Avadel Pharmaceuticals 的董事会成员及首席执行官的背景。</li>
<li><strong>其他高绩效股票</strong>：是否还有其他股票提供更好的前景和良好的业绩记录？在这里探索我们免费的优秀股票清单。</li>
</ol>
<p>如果您想交易 Avadel Pharmaceuticals，请在专业人士信赖的最低成本平台 Interactive Brokers 开设账户。</p>
<p>IBKR 在 200 多个国家和地区拥有客户，并可访问 160 个市场，让您可以通过一个集成账户交易股票、期权、期货、外汇、债券和基金。</p>
<p>享受无隐藏费用、无账户最低限额，以及低至 0.03% 的外汇转换率，远远优于大多数经纪商提供的服务。</p>
<p>赞助内容</p>

Avadel制药

<p>Avadel Pharmaceuticals plc（纳斯达克代码：AVDL）是一家生物制药公司，预计将在 2024 年亏损 4900 万美元后，于 12 个月内实现盈亏平衡。分析师预计 2024 年将出现最终亏损，随后在 2025 年实现 1500 万美元的利润，这需要平均年增长率达到 48%。然而，该公司的债务水平较高，达到股本的 50%，这带来了投资风险。建议进一步探讨 Avadel 的基本面和管理层，以获得详细分析</p>

<p>With the business potentially at an important milestone, we thought we'd take a closer look at <strong>Avadel Pharmaceuticals plc's (NASDAQ:AVDL)</strong> future prospects. Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The US$742m market-cap company announced a latest loss of US$49m on 31 December 2024 for its most recent financial year result. As path to profitability is the topic on Avadel Pharmaceuticals' investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.</p>
<div class="lb-trans"><p>随着业务可能达到一个重要的里程碑，我们认为有必要更深入地了解 <strong>Avadel Pharmaceuticals plc（纳斯达克：AVDL）</strong> 的未来前景。Avadel Pharmaceuticals plc 是一家在美国运营的生物制药公司。这家市值为 7.42 亿美元的公司在 2024 年 12 月 31 日公布了最新的亏损为 4900 万美元，作为其最近的财务年度结果。由于盈利之路是 Avadel Pharmaceuticals 投资者关注的话题，我们决定评估市场情绪。在本文中，我们将讨论对公司增长的预期以及分析师预计何时会实现盈利。</p>
</div><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>
<div class="lb-trans"><p>特朗普承诺要 “释放” 美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
</div><p>According to the 10 industry analysts covering Avadel Pharmaceuticals, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$15m in 2025. So, the company is predicted to breakeven approximately 12 months from now or less. We calculated the rate at which the company must grow to meet the consensus forecasts predicting breakeven within 12 months. It turns out an average annual growth rate of 48% is expected, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.</p>
<div class="lb-trans"><p>根据覆盖 Avadel Pharmaceuticals 的 10 位行业分析师的共识，盈亏平衡点即将到来。他们预计公司将在 2024 年遭受最后一次亏损，然后在 2025 年实现 1500 万美元的正利润。因此，预计公司将在大约 12 个月内或更短时间内实现盈亏平衡。我们计算了公司必须以多快的速度增长才能满足预测在 12 个月内实现盈亏平衡的共识预测。结果显示，预计平均年增长率为 48%，这表明分析师对公司的信心很高。如果业务增长速度较慢，盈利的时间将会比预期更晚。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/28567-earnings-per-share-growth-1-dark/1744550329605" alt="" original-src="https://images.simplywall.st/asset/chart/28567-earnings-per-share-growth-1-dark/1744550329605"/></p>
<p>NasdaqGM:AVDL Earnings Per Share Growth April 13th 2025</p>
<div class="lb-trans"><p>纳斯达克 GM:AVDL 每股收益增长 2025 年 4 月 13 日</p>
</div><p>Given this is a high-level overview, we won’t go into details of Avadel Pharmaceuticals' upcoming projects, though, keep in mind that generally a pharma company has lumpy cash flows which are contingent on the drug and stage of product development the business is in. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.</p>
<div class="lb-trans"><p>鉴于这是一个高层次的概述，我们不会详细讨论 Avadel Pharmaceuticals 即将推出的项目，但请记住，通常制药公司的现金流波动较大，这取决于药物和产品开发阶段。因此，特别是在公司处于投资期时，高增长率并不罕见。</p>
</div><p>Check out our latest analysis for Avadel Pharmaceuticals</p>
<div class="lb-trans"><p>查看我们对 Avadel Pharmaceuticals 的最新分析</p>
</div><p>One thing we would like to bring into light with Avadel Pharmaceuticals is its relatively high level of debt. Generally, the rule of thumb is debt shouldn’t exceed 40% of your equity, which in Avadel Pharmaceuticals' case is 50%. A higher level of debt requires more stringent capital management which increases the risk in investing in the loss-making company.</p>
<div class="lb-trans"><p>我们想要强调的一点是 Avadel Pharmaceuticals 相对较高的债务水平。一般来说，经验法则是债务不应超过股本的 40%，而在 Avadel Pharmaceuticals 的情况下为 50%。较高的债务水平需要更严格的资本管理，这增加了投资于这家亏损公司的风险。</p>
</div><h2>Next Steps:</h2>
<div class="lb-trans"><h2>下一步：</h2>
</div><p>There are key fundamentals of Avadel Pharmaceuticals which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Avadel Pharmaceuticals, take a look at Avadel Pharmaceuticals' company page on Simply Wall St. We've also compiled a list of essential factors you should look at:</p>
<div class="lb-trans"><p>Avadel Pharmaceuticals 的一些关键基本面在本文中未被覆盖，但我们必须再次强调，这仅仅是一个基本概述。要更全面地了解 Avadel Pharmaceuticals，请查看 Avadel Pharmaceuticals 在 Simply Wall St 的公司页面。我们还整理了一份您应该关注的关键因素清单：</p>
</div><ol>
<li><strong>Valuation</strong>: What is Avadel Pharmaceuticals worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Avadel Pharmaceuticals is currently mispriced by the market.</li>
<li><strong>Management Team</strong>: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Avadel Pharmaceuticals’s board and the CEO’s background .</li>
<li><strong>Other High-Performing Stocks</strong>: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.</li>
</ol>
<div class="lb-trans"><ol>
<li><strong>估值</strong>：Avadel Pharmaceuticals 今天值多少钱？未来的增长潜力是否已经反映在价格中？我们免费研究报告中的内在价值信息图有助于可视化 Avadel Pharmaceuticals 目前是否被市场低估。</li>
<li><strong>管理团队</strong>：经验丰富的管理团队能够增强我们对业务的信心——请查看 Avadel Pharmaceuticals 的董事会成员及首席执行官的背景。</li>
<li><strong>其他高绩效股票</strong>：是否还有其他股票提供更好的前景和良好的业绩记录？在这里探索我们免费的优秀股票清单。</li>
</ol>
</div><p>If you're looking to trade Avadel Pharmaceuticals, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.</p>
<div class="lb-trans"><p>如果您想交易 Avadel Pharmaceuticals，请在专业人士信赖的最低成本平台 Interactive Brokers 开设账户。</p>
</div><p>With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.</p>
<div class="lb-trans"><p>IBKR 在 200 多个国家和地区拥有客户，并可访问 160 个市场，让您可以通过一个集成账户交易股票、期权、期货、外汇、债券和基金。</p>
</div><p>Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.</p>
<div class="lb-trans"><p>享受无隐藏费用、无账户最低限额，以及低至 0.03% 的外汇转换率，远远优于大多数经纪商提供的服务。</p>
</div><p>Sponsored Content</p>
<div class="lb-trans"><p>赞助内容</p>
</div>

亏损中的 Avadel Pharmaceuticals plc（纳斯达克股票代码：AVDL）即将实现收支平衡